Shire (SHPG) Issuance of Stock : $223 Mil (TTM As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire Issuance of Stock?

Shire's Issuance of Stock for the three months ended in Sep. 2018 was $47 Mil.

Shire's Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2018 was $223 Mil.

Shire Issuance of Stock Historical Data

The historical data trend for Shire's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Issuance of Stock Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Issuance of Stock

Get a 7-Day Free Trial

17.20

17.40

16.60

169.20

134.10

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Issuance of Stock	Get a 7-Day Free Trial															12.70	41.90	40.50	93.20	47.10

Shire Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $223 Mil.

Shire Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Shire's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Issuance of Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085